 | |
| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | 1992 |
| Headquarters | , Germany |
Key people | Dr. Jean-Paul Kress (CEO) Sung Lee (CFO) Dr. Malte Peters (Chief Research & Development Officer) Dr. Roland Wandeler (CCO) Dr. Marc Cluzel (chairman of Supervisory Board) |
| Products | Immunotherapy |
| Revenue | €327.7 million (2020)[1] |
| €27.4 million (2020)[1] | |
| €97.9 million (2020)[1] | |
| Total assets | €1,659.5 million (end 2020)[1] |
| Total equity | €621.3 million (end 2020)[1] |
Number of employees | 615 (end 2020)[1] |
| Website | morphosys |
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases.[1][2][3] While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG is listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024.[4]
- ^ a b c d e f g "Annual Report 2020". MorphoSys. Retrieved 29 April 2021.
- ^ "MorphoSys' therapeutic pipeline". MorphoSys.
- ^ "Form 20-F". U.S. Securities and Exchange Commission.
- ^ Cite error: The named reference
:0was invoked but never defined (see the help page).
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search